CD8A and neoplasm: While PLELC tumor cells have been reported to express high PD-L1 levels, tumor-specific CD8+ tumor-infiltrating lymphocytes (TILs) only partially express PD-1, resulting in a limited response to immune checkpoint inhibitors [13].